NL-OMON45596已完成3 期
A randomized, double-blind, active control, multicenter study to evaluate the efficacy at week 52 of subcutaneously administered secukinumab monotherapy compared with subcutaneously administered adalimumab monotherapy in patients with active psoriatic arthritis - CAIN457F2366 (EXCEED 1)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Diagnosis of PsA classified by CASPAR; Rheumatoid factor and anti-CCP antibodies negative; diagnosis of active plaque psoriasis, with at least one psoriatic plaque of *2cm diameter or nail changes consistent with psoriasis or documented history of plaque psoriasis; inadequate control of symptoms with NSAIDs; inadequate control of symptoms with a conventional DMARD.;Other protocol-defined inclusion criteria may apply. See protocol for more details.
排除标准
- •Pregnant or nursing women, evidence of ongoing infectious or malignant process; previous exposure to any biologic drug for Psoriatic Arthritis or Psoriasis; subjects taking high potency opioid analgesics; ongoing use of prohibited psoriasis treatments / medications; previous treatment with any cell-depleting therapies including but not limited to anti-CD20, investigational agents;Other protocol-defined exclusion criteria may apply. See protocol for more details.
研究者
相似试验
进行中（未招募）
1 期
Efficacy of secukinumab compared to adalimumab in patients with psoriatic arthritisPsoriatic ArthritisMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2015-004477-32-PLovartis Pharma AG853
进行中（未招募）
1 期
Efficacy of secukinumab compared to adalimumab in patients with psoriatic arthritisMedDRA version: 21.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 100000004859Psoriatic ArthritisEUCTR2015-004477-32-LTovartis Pharma AG853
进行中（未招募）
1 期
Efficacy of secukinumab compared to adalimumab in patients with psoriatic arthritisPsoriatic ArthritisMedDRA version: 20.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 100000004859EUCTR2015-004477-32-CZovartis Pharma AG853
进行中（未招募）
1 期
Efficacy of secukinumab compared to adalimumab in patients with psoriatic arthritisPsoriatic ArthritisMedDRA version: 21.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 100000004859EUCTR2015-004477-32-DKovartis Pharma AG853
进行中（未招募）
1 期
Efficacy of secukinumab compared to adalimumab in patients with psoriatic arthritisMedDRA version: 20.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859Psoriatic ArthritisEUCTR2015-004477-32-BGovartis Pharma AG853